Predicting Survival in Pancreatic Cancer After Surgery
Author Information
Author(s): Qin Dailei, Xi Pu, Huang Kewei, Jiang Lingmin, Yao Zehui, Wei Ran, Li Shengping
Primary Institution: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
Hypothesis
The study aimed to explore independent prognostic factors for post-progression-free survival (PPFS) in recurrent pancreatic ductal adenocarcinoma (PDAC) patients after radical surgery.
Conclusion
Multi-agent chemotherapy is recommended for PDAC patients after surgery, and a nomogram was developed for predicting PPFS.
Supporting Evidence
- Patients receiving multi-agent chemotherapy after surgery had longer PPFS than those receiving single-agent chemotherapy.
- Local recurrence with distant metastases predicted shorter PPFS.
- Factors such as early recurrence and lympho-vascular invasion were associated with worse outcomes.
Takeaway
Doctors can use a special chart to help predict how long patients with pancreatic cancer will live after their cancer comes back, and using more than one type of medicine can help them live longer.
Methodology
The study involved a retrospective analysis of 200 recurrent PDAC patients, using univariate and multivariate Cox regression to identify prognostic factors and constructing a nomogram for PPFS prediction.
Potential Biases
Selection bias may have affected the results due to the exclusion of patients with certain conditions.
Limitations
The study was a single-center retrospective design, which may limit the generalizability of the results.
Participant Demographics
The study included 200 recurrent PDAC patients, with a mix of genders and ages, but specific demographic details were not provided.
Statistical Information
P-Value
p=0.009
Confidence Interval
1.24 – 8.42
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website